Mostrar el registro sencillo del ítem

dc.contributor.authorMoreno Estar, Sara 
dc.contributor.authorSerrano, Sofía
dc.contributor.authorArévalo Martínez, Marycarmen 
dc.contributor.authorCidad Velasco, María Del Pilar 
dc.contributor.authorLópez López, José Ramón 
dc.contributor.authorSantos García, María Mercedes 
dc.contributor.authorPérez García, María Teresa 
dc.contributor.authorArias Vallejo, Francisco Javier 
dc.date.accessioned2024-01-30T13:49:09Z
dc.date.available2024-01-30T13:49:09Z
dc.date.issued2020
dc.identifier.citationActa Biomater . 2020 Oct 1:115:264-274. doi: 10.1016/j.actbio.2020.07.053. Epub 2020 Aug 6.es
dc.identifier.issn1742-7061es
dc.identifier.urihttps://uvadoc.uva.es/handle/10324/65357
dc.description.abstractCoronary artery disease (CAD) is the most common cardiovascular disorder. Vascular surgery strategies for coronary revascularization (either percutaneous or open) show a high rate of failure because of restenosis of the vessel, due to phenotypic switch of vascular smooth muscle cells (VSMCs) leading to proliferation and migration. We have previously reported that the inhibition of Kv1.3 channel function with selective blockers represents an effective strategy for the prevention of restenosis in human vessels used for coronary angioplasty procedures. However, delivery systems for controlled release of these drugs have not been investigated. Here we tested the efficacy of several formulations of elastin like recombinamers (ELRs) hydrogels to deliver the Kv1.3 blocker PAP-1 in various restenosis models. The dose and time course of PAP-1 release from ELRs click hydrogels was able to inhibit human VSMC proliferation in vitro as well as remodeling of human vessels in organ culture and restenosis in in vivo models. We conclude that this combination of active compound and advanced delivery method could improve the outcomes of vascular surgery in patients. STATEMENT OF SIGNIFICANCE: Vascular surgery strategies for coronary revascularization show a high rate of failure, because of occlusion (restenosis) of the vessel, due to vascular smooth muscle cells proliferation and migration. We have previously reported that blockers of Kv1.3 channels represent an effective anti-restenosis therapy, but delivery systems for their controlled release have not being explored. Here we tested the efficacy of several formulations of elastin like recombinamers (ELRs) hydrogels to deliver the Kv1.3 blocker PAP-1 in various restenosis models, both in vivo and in vitro, and also in human vessels. We demonstrated that combination of active compound and advanced delivery method could improve the outcomes of vascular surgery in patients.es
dc.format.mimetypeapplication/pdfes
dc.language.isospaes
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses
dc.titleElastin-like recombinamer-based devices releasing Kv1.3 blockers for the prevention of intimal hyperplasia: An in vitro and in vivo studyes
dc.typeinfo:eu-repo/semantics/articlees
dc.identifier.doi10.1016/j.actbio.2020.07.053es
dc.identifier.publicationfirstpage264es
dc.identifier.publicationlastpage274es
dc.identifier.publicationtitleActa Biomaterialiaes
dc.identifier.publicationvolume115es
dc.peerreviewedSIes
dc.type.hasVersioninfo:eu-repo/semantics/acceptedVersiones


Ficheros en el ítem

Thumbnail

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem